In a significant development, Bajaj Healthcare Limited (BHL) has announced securing exclusive rights for the manufacturing, distribution, and sale of Magnesium L Threonate (Magtein®) in India. The rights were granted by Threotech LLC, a prominent international firm, further strengthening BHL’s foothold in the pharmaceutical industry.
Bajaj Healthcare’s collaboration with Threotech LLC has evolved significantly with this agreement. The company now holds licensing rights to not only manufacture the finished formulation of Magnesium L Threonate but also explore marketing collaborations with leading branded pharmaceutical firms in India. This step reinforces BHL’s commitment to delivering innovative healthcare solutions.
BHL has been a trusted supplier of the Active Pharmaceutical Ingredient (API) for Magtein® in the United States under an exclusive arrangement. Magtein® is a recognised brand with an estimated sales value of approximately $438 million globally, showcasing its demand and market potential.
Speaking about this milestone, Mr Anil Jain, Managing Director of Bajaj Healthcare Limited, remarked:“ Our collaboration with Threotech LLC has taken an exciting step forward… We are well-positioned to unlock the product’s full potential in the Indian market.”
With a robust domestic presence and proven expertise in manufacturing and distribution, BHL is poised to make Magnesium L Threonate a significant addition to its portfolio.
Magnesium L Threonate is a nutraceutical product known for its potential cognitive health benefits. Its innovative formulation positions it as a unique offering in the Indian market, targeting a growing consumer base for wellness and health products.
Established in 1993, Bajaj Healthcare is a leading manufacturer of APIs, intermediates, and formulations. With state-of-the-art facilities and a presence in global markets like Europe, the USA, Australia, and South America, the company continues to enhance its capabilities to meet advanced and emerging market demands.
As of 11:04 AM today, the share price is up by 11.94% at ₹628.60.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 17, 2025, 2:58 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
